These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17471972)

  • 1. [Antisense drug development].
    Funato T; Takeda M
    Tanpakushitsu Kakusan Koso; 2006 Dec; 51(16 Suppl):2515-20. PubMed ID: 17471972
    [No Abstract]   [Full Text] [Related]  

  • 2. [Future prospects of RNA interference in cancer therapies].
    Ashihara E
    Rinsho Ketsueki; 2009 Oct; 50(10):1577-88. PubMed ID: 19915369
    [No Abstract]   [Full Text] [Related]  

  • 3. RNA interference screening for the discovery of oncology targets.
    Quon K; Kassner PD
    Expert Opin Ther Targets; 2009 Sep; 13(9):1027-35. PubMed ID: 19650760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Making sense of antisense and interference.
    Morrow T
    Manag Care; 2003 Nov; 12(11):62-3. PubMed ID: 14666589
    [No Abstract]   [Full Text] [Related]  

  • 5. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to design an antisense oligodeoxynucleotide experiment: a consensus approach.
    Stein CA
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):129-32. PubMed ID: 9593051
    [No Abstract]   [Full Text] [Related]  

  • 7. RNA interference against viruses: strike and counterstrike.
    Haasnoot J; Westerhout EM; Berkhout B
    Nat Biotechnol; 2007 Dec; 25(12):1435-43. PubMed ID: 18066040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-targeted therapies for the central nervous system.
    Miller TM; Smith RA; Kordasiewicz H; Kaspar BK
    Arch Neurol; 2008 Apr; 65(4):447-51. PubMed ID: 18268183
    [No Abstract]   [Full Text] [Related]  

  • 9. [RNA in drug development].
    Kozu T
    Tanpakushitsu Kakusan Koso; 2003 Mar; 48(4 Suppl):540-8. PubMed ID: 12696165
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapeutic perspectives on antisense oligonucleotides].
    Mazza P
    Boll Chim Farm; 1992 Nov; 131(10):355-62. PubMed ID: 1296702
    [No Abstract]   [Full Text] [Related]  

  • 11. Targets for treatment success.
    Simon R
    Nat Clin Pract Oncol; 2006 Jan; 3(1):1. PubMed ID: 16407857
    [No Abstract]   [Full Text] [Related]  

  • 12. An ENU-induced mutant archive for gene targeting in rats.
    Mashimo T; Yanagihara K; Tokuda S; Voigt B; Takizawa A; Nakajima R; Kato M; Hirabayashi M; Kuramoto T; Serikawa T
    Nat Genet; 2008 May; 40(5):514-5. PubMed ID: 18443587
    [No Abstract]   [Full Text] [Related]  

  • 13. A role for microRNAs in the development of the immune system and in the pathogenesis of cancer.
    Kanellopoulou C; Monticelli S
    Semin Cancer Biol; 2008 Apr; 18(2):79-88. PubMed ID: 18291671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells.
    Childs-Disney JL; Disney MD
    Annu Rev Pharmacol Toxicol; 2016; 56():123-40. PubMed ID: 26514201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of RNA interference.
    Stevenson M
    N Engl J Med; 2004 Oct; 351(17):1772-7. PubMed ID: 15496626
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of target site accessibility on the design of effective siRNAs.
    Tafer H; Ameres SL; Obernosterer G; Gebeshuber CA; Schroeder R; Martinez J; Hofacker IL
    Nat Biotechnol; 2008 May; 26(5):578-83. PubMed ID: 18438400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of optimal sites for TGFB1 gene silencing by chitosan-TPP nanoparticle-mediated delivery of shRNA.
    Wang SL; Yao HH; Guo LL; Dong L; Li SG; Gu YP; Qin ZH
    Cancer Genet Cytogenet; 2009 Apr; 190(1):8-14. PubMed ID: 19264227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The identification and validation of common disease genes: relevance to the drug development process.
    Holmberg M; Lejon K
    Curr Opin Mol Ther; 2001 Dec; 3(6):533-7. PubMed ID: 11804267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Regulatory system of HIV transcription as a feasible therapeutic target].
    Imai K; Okamoto T
    Tanpakushitsu Kakusan Koso; 2007 Aug; 52(10 Suppl):1121-7. PubMed ID: 17824227
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification of sequence motifs significantly associated with antisense activity.
    McQuisten KA; Peek AS
    BMC Bioinformatics; 2007 Jun; 8():184. PubMed ID: 17555590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.